FDA批准牛痘免疫球蛋白静脉注射剂治疗天花疫苗并发症2005年2月18日,美国FDA批准DynPort Vaccine公司生产的牛痘免疫球蛋白静脉注射剂上市。这是第一个获批用于治疗由接种天花疫苗后引起的某些罕见并发症的人血浆衍生物注射剂。接种天花疫苗最常见的不良反应均较轻,通常不需治 FDA approves vaccinia immunoglobulin intravenous injection for the treatment of smallpox vaccine complications February 18, 2005, the United States FDA approved DynPort Vaccine vaccinia immunoglobulin intravenous injection. This is the first injection of a human plasma derivative approved for the treatment of some of the rare complications caused by vaccination with a smallpox vaccine. Vaccination of smallpox vaccines are the most common adverse reactions, usually without treatment